Coronavirus Vaccine: AIIMS Patna to begin human trails in India with 18 volunteers

By Lokmat English Desk | Published: July 13, 2020 06:21 PM2020-07-13T18:21:01+5:302020-07-13T18:21:36+5:30

The All India Institute of Medical Science (AIIMS) Patna will start the human trail of coronavirus vaccine from today. ...

Coronavirus Vaccine: AIIMS Patna to begin human trails in India with 18 volunteers | Coronavirus Vaccine: AIIMS Patna to begin human trails in India with 18 volunteers

Coronavirus Vaccine: AIIMS Patna to begin human trails in India with 18 volunteers

The All India Institute of Medical Science (AIIMS) Patna will start the human trail of coronavirus vaccine from today.  For the purpose of the trials, the All India Institute of Medical Sciences (AIIMS) in Patna has selected 18 volunteers on whom the vaccine trails will be conducted. Only the Bharat Biotech International Ltd and the Zydus Cadila pharmaceutical companies' indigenously developed vaccine prototypes have got an approval for the human trials from the Drugs Controller General of India.

Around seven Indian firms are currently working on coronavirus vaccines. Among them, Bharat Biotech's 'Covaxin' vaccine prototype was the first to get a regulatory nod from the DGCI to begin Phase I and Phase II human trials. AIIMS Patna is one of the 12 institutes selected by the Indian Council of Medical Research (ICMR) for conducting the coronavirus vaccine trials. Several people contacted the AIIMS hospital to take part in the trail but only 18 people aged between 18 to 55 years were selected for the process. 

The selected volunteers will first go through a medical check-up on Monday, and after their reports are analysed, the subjects will further proceed for the trail. As per the ICMR guidelines, the first dose of the vaccine will be given to only those whose reports will be fine.After the first dose of the vaccine, the patient will be under a doctor's supervision for 2 to 3 hours after which they will be sent home.A total of three dosages of injection will be given to the patients to complete the trial process. 

Open in app